Similar articles for PMID: 29054093

Year	Number of Results
2001	1
2003	1
2008	1
2009	2
2010	9
2011	6
2012	7
2013	12
2014	14
2015	12
2016	15
2017	8
2018	6
2019	5
2020	4
2021	2
2022	1
2024	0

1

The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.

Chellappan DK, Chellian J, Ng ZY, Sim YJ, Theng CW, Ling J, Wong M, Foo JH, Yang GJ, Hang LY, Nathan S, Singh Y, Gupta G. Chellappan DK, et al. Biomed Pharmacother. 2017 Dec;96:768-781. doi: 10.1016/j.biopha.2017.10.058. Epub 2017 Nov 6. Biomed Pharmacother. 2017. PMID: 29054093 Review.

2

Pazopanib in ovarian cancer.

McLachlan J, Banerjee S. McLachlan J, et al. Expert Rev Anticancer Ther. 2015;15(9):995-1005. doi: 10.1586/14737140.2015.1081383. Epub 2015 Aug 20. Expert Rev Anticancer Ther. 2015. PMID: 26296187 Review.

3

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Bianconi M, Faloppi L, Loretelli C, Zizzi A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Burattini L, Montironi R, Scartozzi M, Cascinu S. Bianconi M, et al. Oncotarget. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229. Oncotarget. 2016. PMID: 27175586 Free PMC article.

4

Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Chamberlain FE, Wilding C, Jones RL, Huang P. Chamberlain FE, et al. Expert Opin Investig Drugs. 2019 Jun;28(6):505-511. doi: 10.1080/13543784.2019.1607291. Epub 2019 Apr 22. Expert Opin Investig Drugs. 2019. PMID: 31010343 Review.

5

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

Hamberg P, Verweij J, Sleijfer S. Hamberg P, et al. Oncologist. 2010;15(6):539-47. doi: 10.1634/theoncologist.2009-0274. Epub 2010 May 28. Oncologist. 2010. PMID: 20511320 Free PMC article. Review.

6

Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.

Yafai Y, Yang XM, Niemeyer M, Nishiwaki A, Lange J, Wiedemann P, King AG, Yasukawa T, Eichler W. Yafai Y, et al. Eur J Pharmacol. 2011 Sep;666(1-3):12-8. doi: 10.1016/j.ejphar.2011.05.016. Epub 2011 May 20. Eur J Pharmacol. 2011. PMID: 21620822

7

Pazopanib: an antiangiogenic drug in perspective.

Castaneda CA, Gomez HL. Castaneda CA, et al. Future Oncol. 2009 Nov;5(9):1335-48. doi: 10.2217/fon.09.112. Future Oncol. 2009. PMID: 19903063 Review.

8

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK. Pick AM, et al. Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Clin Ther. 2012. PMID: 22341567 Review.

9

Effect of pazopanib on tumor microenvironment and liposome delivery.

Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW. Tailor TD, et al. Mol Cancer Ther. 2010 Jun;9(6):1798-808. doi: 10.1158/1535-7163.MCT-09-0856. Epub 2010 Jun 1. Mol Cancer Ther. 2010. PMID: 20515941 Free PMC article.

10

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT. Duffaud F, et al. Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25. Eur J Cancer. 2015. PMID: 26321011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year